



## JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office. T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)  
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-46181100, 46109900  
CIN No. L74899DL1978PLC009181

Date: February 13<sup>th</sup>, 2020

|   |  |
|---|--|
| To,<br>The Department of Corporate Services-<br>Listing<br><b>BSE Limited</b><br>Phiroze Jeejeebhoy Towers,<br>Dalal Street,<br>Mumbai-400 001<br><b>Scrip Code: 507789</b> | To,<br>The Manager- Listing<br><b>National Stock Exchange of India Ltd.</b><br>Exchange Plaza, C-1, Block G,<br>Bandra Kurla Complex,<br>Bandra (E)<br>Mumbai – 400 051<br><b>Symbol: JAGSNPHARM</b> |
|---|--|

**Subject: Submission of Un-Audited Financial Results Along with Limited Review Report for the Quarter and Nine Months ended 31<sup>st</sup> December, 2019.**

Dear Sir,


In terms of the provisions of Regulation 33 (3) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Un-Audited Financial Results for the Quarter and Nine Months ended 31<sup>st</sup> December, 2019, duly approved by the Board at its meeting held on 13<sup>th</sup> February, 2020.

The Limited Review Report on the Un-Audited Financial Results for the Quarter and Nine Months ended 31<sup>st</sup> December, 2019 in accordance with Regulation 33 (3)(c)(i) of the SEBI (Listing Obligations and Disclosure requirements) Regulations 2015 is also enclosed herewith.

Kindly take the above on record & oblige.

Thanking You,

For JAGSONPAL PHARMACEUTICALS LIMITED

  
Nandita Singh

Company Secretary & Compliance Officer





# JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)  
 Fax : 0091-11-26498341, 26494708, Phone : 0091-11-46181100, 46109900  
 CIN No. L74899DL1978PLC009181

## Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months Ended 31.12.2019

| Particulars | Standalone  |                |                |                    |                 |                 | Rs. in Lakh |
|-------------|---|----------------|----------------|--------------------|-----------------|-----------------|-------------|
|             | Quarter Ended   |                |                | • Nine Month Ended |                 |                 | 12 Months   |
|             | 31.12.2019  | 30.09.2019     | 31.12.2018     | 31.12.2019         | 31.12.2018      | 31.03.2019      |             |
|             | Unaudited   | Unaudited      | Unaudited      | Unaudited          | Unaudited       | Audited         |             |
| <b>1</b>    | <b>Income from operations</b>   |                |                |                    |                 |                 |             |
| a           | 4201.04   | 4180.59        | 4189.45        | 12905.03           | 12842.34        | 16682.56        |             |
| b           | 0.00  | 0.00           | 0.00           | 0.00               | 0.00            | 0.00            |             |
|             | <b>4201.04</b>  | <b>4180.59</b> | <b>4189.45</b> | <b>12905.03</b>    | <b>12842.34</b> | <b>16682.56</b> |             |
| <b>2</b>    | <b>Other Income</b>   |                |                |                    |                 |                 |             |
|             | 65.08   | 44.38          | 27.86          | 176.58             | 54.95           | 142.90          |             |
| <b>3</b>    | <b>Total Income [ 1+2]</b>  |                |                |                    |                 |                 |             |
|             | <b>4266.12</b>  | <b>4224.97</b> | <b>4217.31</b> | <b>13081.61</b>    | <b>12897.29</b> | <b>16825.46</b> |             |
| <b>4</b>    | <b>Expenses</b>   |                |                |                    |                 |                 |             |
| a           | 1244.12   | 756.22         | 1290.77        | 3173.47            | 3132.32         | 3878.66         |             |
| b           | 535.02  | 461.38         | 399.80         | 1471.23            | 924.69          | 1464.08         |             |
| c           | -380.60   | 371.10         | 106.07         | 191.61             | 1840.63         | 1941.82         |             |
| d           | 1461.64   | 1246.90        | 1274.04        | 4023.05            | 3601.22         | 4661.10         |             |
| e           | 10.12   | 14.81          | 10.42          | 36.70              | 47.24           | 74.55           |             |
| f           | 25.95   | 26.72          | 23.06          | 81.28              | 73.45           | 101.58          |             |
| g           | 1084.46   | 1094.21        | 898.72         | 3314.77            | 2751.16         | 3803.39         |             |
|             | <b>3980.71</b>  | <b>3971.34</b> | <b>4002.88</b> | <b>12292.11</b>    | <b>12370.71</b> | <b>15925.18</b> |             |
| <b>5</b>    | <b>Profit before exceptional items and taxes (3-4)</b>                                    |                |                |                    |                 |                 |             |
|             | <b>285.41</b>   | <b>253.63</b>  | <b>214.43</b>  | <b>789.50</b>      | <b>526.58</b>   | <b>900.28</b>   |             |
| 6           | 0.00  | 0.00           | 0.00           | 0.00               | 0.00            | 0.00            |             |
| <b>7</b>    | <b>Profit before tax [5-6]</b>  |                |                |                    |                 |                 |             |
|             | <b>285.41</b>   | <b>253.63</b>  | <b>214.43</b>  | <b>789.50</b>      | <b>526.58</b>   | <b>900.28</b>   |             |
| 8           | 57.09   | 50.72          | 40.00          | 157.90             | 102.43          | 178.67          |             |
| <b>9</b>    | <b>Net Profit for the period [7-8]</b>  |                |                |                    |                 |                 |             |
|             | <b>228.32</b>   | <b>202.91</b>  | <b>174.43</b>  | <b>631.60</b>      | <b>424.15</b>   | <b>721.61</b>   |             |
| 10          | <b>Other Comprehensive Income</b>   |                |                |                    |                 |                 |             |
| A           | <b>(i) Items that will not be classified to profit or loss</b>                            |                |                |                    |                 |                 |             |
|             | 0.00  | 0.00           | 0.00           | 0.00               | 0.00            | 0.00            |             |
|             | <b>(ii) Income tax relating to items that will not be reclassified to profit and loss</b> |                |                |                    |                 |                 |             |
|             | 0.00  | 0.00           | 0.00           | 0.00               | 0.00            | 0.00            |             |
| <b>11</b>   | <b>Total Other Comprehensive Income [A(i) + A(ii)]</b>                                    |                |                |                    |                 |                 |             |
|             | <b>0.00</b>   | <b>0.00</b>    | <b>0.00</b>    | <b>0.00</b>        | <b>0.00</b>     | <b>0.00</b>     |             |
| <b>12</b>   | <b>Total Comprehensive Income [9+11]</b>  |                |                |                    |                 |                 |             |
|             | <b>228.32</b>   | <b>202.91</b>  | <b>174.43</b>  | <b>631.60</b>      | <b>424.15</b>   | <b>721.61</b>   |             |
| 13          | <b>Paid up Equity Share Capital (Face value Rs. 5/- per share)</b>                        |                |                |                    |                 |                 |             |
|             | 1309.90   | 1309.90        | 1309.90        | 1309.90            | 1309.90         | 1309.90         |             |
| <b>14</b>   | <b>Earnings Per Share of Rs 5/- each (before and after extraordinary items)</b>           |                |                |                    |                 |                 |             |
| a.          | 0.87  | 0.77           | 0.67           | 2.41               | 1.62            | 2.75            |             |
| b.          | 0.87  | 0.77           | 0.67           | 2.41               | 1.62            | 2.75            |             |

### Notes :

- The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on February 13, 2020. The results have been subjected to Unaudited review by statutory Auditors of the Company.
- In line with the provisions of Ind AS 18, the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
- Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.
- The above results are available on website of the company [www.jagsonpal.com](http://www.jagsonpal.com) and on the Website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).
- The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder.
- The revenue for the quarter ended 31-12-2019, is reported net of GST.
- Provision for taxation includes provision for current tax.

By Order of the Board  
 For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar  
 Managing Director

DIN No 00059492

Place : New Delhi

Date : 13-02-2020

Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone : 0091-95129-2275952, 2275953






## LIMITED REVIEW REPORT

The Board of Directors  
Jagsonpal Pharmaceuticals Limited  
T-210-J, Shahpur Jat  
New Delhi-110049

1. We have reviewed the accompanying statement of Unaudited Financial Results of Jagsonpal Pharmaceuticals Limited (the "Company") for the Quarter and Nine Months ended 31<sup>ST</sup> December, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 13<sup>th</sup> February, 2020  
Place: New Delhi

For H. L. Bansal & Co.  
Firm Registration Number: 08563N  
Chartered Accountants



H. L. Bansal  
Proprietor

Membership Number: 086990

UDIN 20086990AAAAAQ9075